{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:52:51Z","timestamp":1782280371987,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","award":["PO18\/00879"],"award-info":[{"award-number":["PO18\/00879"]}],"id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","award":["PO18\/00879"],"award-info":[{"award-number":["PO18\/00879"]}],"id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","award":["PO18\/00879"],"award-info":[{"award-number":["PO18\/00879"]}],"id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","award":["PO18\/00879"],"award-info":[{"award-number":["PO18\/00879"]}],"id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","award":["PO18\/00879"],"award-info":[{"award-number":["PO18\/00879"]}],"id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","award":["PO18\/00879"],"award-info":[{"award-number":["PO18\/00879"]}],"id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","award":["PO18\/00879"],"award-info":[{"award-number":["PO18\/00879"]}],"id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","award":["PO18\/00879"],"award-info":[{"award-number":["PO18\/00879"]}],"id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-025-05493-5","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T15:26:24Z","timestamp":1754580384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Multiple first-line therapeutic strategies to mitigate artemisinin resistance: cost analysis of a pilot study from a health system perspective in Kaya health district, Burkina Faso"],"prefix":"10.1186","volume":"24","author":[{"given":"Rosemonde M.","family":"Guissou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Mo\u00efse T.","family":"Kabor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issiaka","family":"Soulama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Hien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacouba","family":"Nombr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred B.","family":"Tiono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Burri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sodiomon B.","family":"Sirima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"5493_CR1","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana S-I, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385:1163\u201371.","journal-title":"N Engl J Med"},{"key":"5493_CR2","unstructured":"WHO. World malaria report 2024 [Internet]. Geneva, World Health Organization, 2024 [cited 2025 Jun 5]. Available from: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2024"},{"key":"5493_CR3","unstructured":"WHO. Guidelines for the treatment of malaria [Internet]. 3rd ed. Geneva: World Health Organization; 2015 [cited 2023 Feb 17]. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/162441"},{"key":"5493_CR4","unstructured":"WHO. Guidelines for malaria 2021 [Internet]. Geneva, World Health Organization; 2022. Available from: file:\/\/\/C:\/Users\/nitie\/Downloads\/WHO-UCN-GMP-2022.01-Rev.2-eng.pdf"},{"key":"5493_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7371681","volume":"2020","author":"A Derbie","year":"2020","unstructured":"Derbie A, Mekonnen D, Adugna M, Yeshitela B, Woldeamanuel Y, Abebe T. Therapeutic efficacy of artemether-lumefantrine (Coartem\u00ae) for the treatment of uncomplicated falciparum malaria in Africa: a systematic review. J Parasitol Research. 2020;2020: e7371681.","journal-title":"J Parasitol Research"},{"key":"5493_CR6","unstructured":"Ministere de la Sante, Programme National de Lutte contre le Paludisme. Directives Nationales pour la prise en charge du paludisme dans les formations sanitaires du Burkina Faso 2021. 2021."},{"key":"5493_CR7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12936-021-03845-5","volume":"20","author":"C Rasmussen","year":"2021","unstructured":"Rasmussen C, Ringwald P. Is there evidence of anti-malarial multidrug resistance in Burkina Faso? Malar J. 2021;20:320.","journal-title":"Malar J"},{"key":"5493_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12936-021-03585-6","volume":"20","author":"A Gansan\u00e9","year":"2021","unstructured":"Gansan\u00e9 A, Moriarty LF, M\u00e9nard D, Yerbanga I, Ouedraogo E, Sondo P, et al. Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017\u20132018. Malar J. 2021;20:48.","journal-title":"Malar J"},{"key":"5493_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/17512433.2018.1387773","volume":"11","author":"J Achan","year":"2018","unstructured":"Achan J, Mwesigwa J, Edwin CP, D\u2019alessandro U. Malaria medicines to address drug resistance and support malaria elimination efforts. Expert Rev Clin Pharmacol. 2018;11:61\u201370.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"5493_CR10","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s40265-018-0911-9","volume":"78","author":"EA Ashley","year":"2018","unstructured":"Ashley EA, Phyo AP. Drugs in development for malaria. Drugs. 2018;78:861\u201379.","journal-title":"Drugs"},{"key":"5493_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12936-019-2724-z","volume":"18","author":"E Tse","year":"2019","unstructured":"Tse E, Korsik M, Todd M. The past, present and future of anti-malarial medicines. Malar J. 2019;18:93. https:\/\/doi.org\/10.1186\/s12936-019-2724-z.","journal-title":"Malar J"},{"key":"5493_CR12","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/s41467-023-37359-2","volume":"14","author":"M Carucci","year":"2023","unstructured":"Carucci M, Duez J, Tarning J, Garc\u00eda-Barbaz\u00e1n I, Fricot-Monsinjon A, Sissoko A, et al. Safe drugs with high potential to block malaria transmission revealed by a spleen-mimetic screening. Nat Commun. 2023;14:1951.","journal-title":"Nat Commun"},{"key":"5493_CR13","doi-asserted-by":"publisher","first-page":"14216","DOI":"10.1073\/pnas.0804628105","volume":"105","author":"MF Boni","year":"2008","unstructured":"Boni MF, Smith DL, Laxminarayan R. Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci U S A. 2008;105:14216\u201321.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5493_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/1475-2875-9-217","volume":"9","author":"DL Smith","year":"2010","unstructured":"Smith DL, Klein EY, McKenzie FE, Laxminarayan R. Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty. Malar J. 2010;9:217.","journal-title":"Malar J"},{"key":"5493_CR15","doi-asserted-by":"publisher","first-page":"1041896","DOI":"10.3389\/fepid.2022.1041896","volume":"2","author":"MF Boni","year":"2022","unstructured":"Boni MF. Breaking the cycle of malaria treatment failure. Front Epidemiol. 2022;2:1041896.","journal-title":"Front Epidemiol"},{"key":"5493_CR16","unstructured":"WHO. Strategy to respond to antimalarial drug resistance in Africa. Geneva, World Health Organization, 2022."},{"key":"5493_CR17","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1038\/s41467-023-39914-3","volume":"14","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Gao B, Amaratunga C, Dhorda M, Tran TN-A, White NJ, et al. Preventing antimalarial drug resistance with triple artemisinin-based combination therapies. Nat Commun. 2023;14:4568.","journal-title":"Nat Commun"},{"key":"5493_CR18","doi-asserted-by":"publisher","first-page":"14216","DOI":"10.1073\/pnas.0804628105","volume":"105","author":"MF Boni","year":"2008","unstructured":"Boni MF, Smith DL, Laxminarayan R. Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci USA. 2008;105:14216\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5493_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001984","volume":"13","author":"MF Boni","year":"2016","unstructured":"Boni MF, White NJ, Baird JK. The community as the patient in malaria-endemic areas: preempting drug resistance with multiple first-line therapies. PLoS Med. 2016;13: e1001984.","journal-title":"PLoS Med"},{"key":"5493_CR20","doi-asserted-by":"publisher","first-page":"961","DOI":"10.4269\/ajtmh.15-0162","volume":"93","author":"J Pfeil","year":"2015","unstructured":"Pfeil J, Borrmann S, Bassat Q, Mulenga M, Talisuna A, Tozan Y. An economic evaluation of the posttreatment prophylactic effect of dihydroartemisinin\u2013piperaquine versus artemether\u2013lumefantrine for first-line treatment of Plasmodium falciparum malaria across different transmission settings in Africa. Am J Trop Med Hyg. 2015;93:961\u20136.","journal-title":"Am J Trop Med Hyg"},{"key":"5493_CR21","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1038\/ncomms6606","volume":"5","author":"LC Okell","year":"2014","unstructured":"Okell LC, Cairns M, Griffin JT, Ferguson NM, Tarning J, Jagoe G, et al. Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. Nat Commun. 2014;5:5606.","journal-title":"Nat Commun"},{"key":"5493_CR22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/1475-2875-13-363","volume":"13","author":"AT Mori","year":"2014","unstructured":"Mori AT, Ngalesoni F, Norheim OF, Robberstad B. Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania. Malar J. 2014;13:363.","journal-title":"Malar J"},{"key":"5493_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1475-2875-7-4","volume":"7","author":"JD Njau","year":"2008","unstructured":"Njau JD, Goodman CA, Kachur SP, Mulligan J, Munkondya JS, Mchomvu N, et al. The costs of introducing artemisinin-based combination therapy: evidence from district-wide implementation in rural Tanzania. Malar J. 2008;7:4.","journal-title":"Malar J"},{"key":"5493_CR24","unstructured":"Wolf K, Hsi CN. Costing Artemisininbased Combination Therapy and Rapid Diagnostic Tests for Malaria in Democratic Republic of Congo. Partners for Health Reformplus; 2005."},{"key":"5493_CR25","unstructured":"Kindermans J-M. Changing national malaria treatment protocols in Africa: what is the cost and who will pay? M\u00e9decins Sans Fronti\u00e8res; 2002;2002:1."},{"key":"5493_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040220","volume":"11","author":"M Siribie","year":"2021","unstructured":"Siribie M, Tchouatieu A-M, Soulama I, Kabor\u00e9 JMT, Nombr\u00e9 Y, Hien D, et al. Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina Faso. BMJ Open. 2021;11: e040220.","journal-title":"BMJ Open"},{"issue":"1","key":"5493_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-022-04180-z","volume":"21","author":"JMT Kabor\u00e9","year":"2022","unstructured":"Kabor\u00e9 JMT, Siribi\u00e9 M, Hien D, Soulama I, Barry N, Nombr\u00e9 Y, et al. Attitudes, practices, and determinants of community care-seeking behaviours for fever\/malaria episodes in the context of the implementation of multiple first-line therapies for uncomplicated malaria in the health district of Kaya, Burkina Faso. Malar J. 2022;21(1): 155.","journal-title":"Malar J"},{"key":"5493_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-022-04225-3","volume":"21","author":"D Hien","year":"2022","unstructured":"Hien D, Kabor\u00e9 JMT, Siribi\u00e9 M, Soulama I, Barry N, Baguiya A, et al. Stakeholder perceptions on the deployment of multiple first-line therapies for uncomplicated malaria: a qualitative study in the health district of Kaya, Burkina Faso. Malar J. 2022;21: 202.","journal-title":"Malar J"},{"key":"5493_CR29","unstructured":"WHO. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003."},{"issue":"Suppl 7","key":"5493_CR30","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/MLR.0b013e3181a7e401","volume":"47","author":"Lipscomb","year":"2009","unstructured":"Lipscomb, et al. Health Care Costing: Data, Methods, Current Applications. Med Care. 2009;47(Suppl 7):S1-6.","journal-title":"Med Care"},{"key":"5493_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/hec.3306","volume":"25","author":"A Vassall","year":"2016","unstructured":"Vassall A, Mangham-Jefferies L, Gomez GB, Pitt C, Foster N. Incorporating demand and supply constraints into economic evaluations in low-income and middle-income countries: incorporating demand and supply constraints in economic evaluations. Health Econ. 2016;25:95\u2013115.","journal-title":"Health Econ"},{"key":"5493_CR32","unstructured":"Insee. Taux de change de l\u2019euro par rapport aux principales devises [Internet]. Taux de change de l\u2019euro par rapport aux principales devises. Insee. 2022 [cited 2021 Oct 4]. Available from: https:\/\/www.insee.fr\/fr\/statistiques\/2381462#tableau-figure1"},{"key":"5493_CR33","unstructured":"Minist\u00e8re de la Sant\u00e9 et de l\u2019Hygi\u00e8ne Publique Burkina Faso. Annuaire Statistique de la sante 2022_ Burkina Faso [Internet]. 2023 [cited 2024 Jan 27]. Available from: http:\/\/cns.bf\/IMG\/pdf\/annuaire_2022_mshp_signe.pdf"},{"key":"5493_CR34","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/1475-2875-11-422","volume":"11","author":"T Antao","year":"2012","unstructured":"Antao T, Hastings I. Policy options for deploying anti-malarial drugs in endemic countries: a population genetics approach. Malar J. 2012;11:422.","journal-title":"Malar J"},{"key":"5493_CR35","doi-asserted-by":"publisher","first-page":"e758","DOI":"10.1016\/S2214-109X(15)00162-X","volume":"3","author":"TD Nguyen","year":"2015","unstructured":"Nguyen TD, Olliaro P, Dondorp AM, Baird JK, Lam HM, Farrar J, et al. Optimum population-level use of artemisinin combination therapies: a modelling study. Lancet Glob Health. 2015;3:e758\u201366.","journal-title":"Lancet Glob Health"},{"key":"5493_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/1475-2875-8-243","volume":"8","author":"J Chuma","year":"2009","unstructured":"Chuma J, Abuya T, Memusi D, Juma E, Akhwale W, Ntwiga J, et al. Reviewing the literature on access to prompt and effective malaria treatment in Kenya: implications for meeting the Abuja targets. Malar J. 2009;8:243.","journal-title":"Malar J"},{"key":"5493_CR37","first-page":"609","volume":"7","author":"YA Hawbani","year":"2021","unstructured":"Hawbani YA. Impacts of Antimalarial Drugs on Malarial Management Outcome of African Regions. Saudi J Med Pharm Sci. 2021;7:609\u201336.","journal-title":"Saudi J Med Pharm Sci"},{"key":"5493_CR38","first-page":"394","volume":"79","author":"K Yeboah-Antwi","year":"2001","unstructured":"Yeboah-Antwi K, Gyapong JO, Asare IK, Barnish G, Evans DB, Adjei S. Impact of prepackaging antimalarial drugs on cost to patients and compliance with treatment. Bull World Health Organ. 2001;79:394\u20139.","journal-title":"Bull World Health Organ"},{"key":"5493_CR39","first-page":"349","volume":"69","author":"SD Foster","year":"1991","unstructured":"Foster SD. Pricing, distribution, and use of antimalarial drugs. Bull World Health Organ. 1991;69:349\u201363.","journal-title":"Bull World Health Organ"},{"key":"5493_CR40","doi-asserted-by":"publisher","DOI":"10.1080\/23288604.2022.2064731","volume":"8","author":"H Barroy","year":"2022","unstructured":"Barroy H, Kutzin J, Coulibaly S, Bigeard A, Yam\u00e9ogo SP, Caremel J-F, et al. Public financial management as an enabler for health financing reform: evidence from free health care policies implemented in Burkina Faso, Burundi, and Niger. Health Syst Reform. 2022;8: e2064731.","journal-title":"Health Syst Reform"},{"key":"5493_CR41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s41669-017-0021-8","volume":"1","author":"CC Ezenduka","year":"2017","unstructured":"Ezenduka CC, Falleiros DR, Godman BB. Evaluating the treatment costs for uncomplicated malaria at a public healthcare facility in Nigeria and the implications. Pharmacoecon Open. 2017;1:185\u201394.","journal-title":"Pharmacoecon Open"},{"key":"5493_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-307","volume":"12","author":"E Sicuri","year":"2013","unstructured":"Sicuri E, Vieta A, Lindner L, Constenla D, Sauboin C. The economic costs of malaria in children in three sub-Saharan countries: Ghana, Tanzania and Kenya. Malar J. 2013;12: 307.","journal-title":"Malar J"},{"key":"5493_CR43","doi-asserted-by":"publisher","first-page":"759","DOI":"10.4236\/health.2010.27115","volume":"02","author":"I Kon\u00e9","year":"2010","unstructured":"Kon\u00e9 I, Marschall P, Flessa S. Costing of malaria treatment in a rural district hospital. Health. 2010;02:759.","journal-title":"Health"},{"key":"5493_CR44","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jhealeco.2010.03.002","volume":"29","author":"R Laxminarayan","year":"2010","unstructured":"Laxminarayan R, Parry IWH, Smith DL, Klein EY. Should new antimalarial drugs be subsidized? J Health Econom. 2010;29:445\u201356.","journal-title":"J Health Econom"},{"key":"5493_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1475-9276-8-15","volume":"8","author":"J Chuma","year":"2009","unstructured":"Chuma J, Musimbi J, Okungu V, Goodman C, Molyneux C. Reducing user fees for primary health care in Kenya: policy on paper or policy in practice? Int J Equity Health. 2009;8:15.","journal-title":"Int J Equity Health"},{"key":"5493_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2016-000243","volume":"2","author":"G Seidman","year":"2017","unstructured":"Seidman G, Atun R. Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries. BMJ Glob Health. 2017;2: e000243.","journal-title":"BMJ Glob Health"},{"key":"5493_CR47","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/23288604.2019.1596050","volume":"5","author":"M Vledder","year":"2019","unstructured":"Vledder M, Friedman J, Sj\u00f6blom M, Brown T, Yadav P. Improving supply chain for essential drugs in low-income countries: results from a large scale randomized experiment in Zambia. Health Syst Reform. 2019;5:158\u201377.","journal-title":"Health Syst Reform"},{"key":"5493_CR48","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4161\/23288604.2014.968005","volume":"1","author":"P Yadav","year":"2015","unstructured":"Yadav P. Health Product Supply Chains in Developing Countries: Diagnosis of the Root Causes of Underperformance and an Agenda for Reform. Health Syst Reform. 2015;1:142\u201354.","journal-title":"Health Syst Reform"},{"key":"5493_CR49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1475-2875-6-72","volume":"6","author":"AA Amin","year":"2007","unstructured":"Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, Akhwale WS, et al. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J. 2007;6:72.","journal-title":"Malar J"},{"key":"5493_CR50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12936-023-04705-0","volume":"22","author":"RM Guissou","year":"2023","unstructured":"Guissou RM, Amaratunga C, de Haan F, Tou F, Cheah PY, Yerbanga RS, et al. The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso. Malar J. 2023;22:269.","journal-title":"Malar J"},{"key":"5493_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095681","volume":"9","author":"J Pfeil","year":"2014","unstructured":"Pfeil J, Borrmann S, Tozan Y. Dihydroartemisinin-piperaquine vs. artemether-lumefantrine for first-line treatment of uncomplicated malaria in African children: a cost-effectiveness analysis. PLoS ONE. 2014;9: e95681.","journal-title":"PLoS ONE"},{"key":"5493_CR52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4269\/ajtmh.19-0661","volume":"103","author":"JO Yukich","year":"2020","unstructured":"Yukich JO, Scott C, Silumbe K, Larson BA, Bennett A, Finn TP, et al. Cost-effectiveness of focal mass drug administration and mass drug administration with dihydroartemisinin-piperaquine for malaria prevention in Southern Province, Zambia: results of a community-randomized controlled trial. Am J Trop Med Hyg. 2020;103:46\u201353.","journal-title":"Am J Trop Med Hyg"},{"key":"5493_CR53","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S0140-6736(18)30291-5","volume":"391","author":"West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)","year":"2018","unstructured":"West African Network for Clinical Trials of Antimalarial Drugs (WANECAM). Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b\/4 trial. Lancet. 2018;391:1378\u201390.","journal-title":"Lancet"},{"key":"5493_CR54","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/1475-2875-11-364","volume":"11","author":"K Kayentao","year":"2012","unstructured":"Kayentao K, Doumbo OK, P\u00e9nali LK, Offianan AT, Bhatt KM, Kimani J, et al. Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Malar J. 2012;11:364.","journal-title":"Malar J"},{"key":"5493_CR55","volume":"3","author":"H Bukirwa","year":"2014","unstructured":"Bukirwa H, Unnikrishnan B, Kramer CV, Sinclair D, Nair S, Tharyan P. Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2014;3: CD006404.","journal-title":"Cochrane Database Syst Rev"},{"key":"5493_CR56","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12936-023-04574-7","volume":"22","author":"CO Falade","year":"2023","unstructured":"Falade CO, Orimadegun AE, Olusola FI, Michael OS, Anjorin OE, Funwei RI, et al. Efficacy and safety of pyronaridine\u2013artesunate versus artemether\u2013lumefantrine in the treatment of acute uncomplicated malaria in children in South-West Nigeria: an open-labelled randomized controlled trial. Malar J. 2023;22:154.","journal-title":"Malar J"},{"key":"5493_CR57","first-page":"CD006404","volume":"6","author":"J Pryce","year":"2022","unstructured":"Pryce J, Taylor M, Fox T, Hine P. Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2022;6:CD006404.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05493-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05493-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05493-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:09:28Z","timestamp":1757354968000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05493-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5493"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05493-5","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the Burkina Faso Health Research Ethics Committee (clearance no. 2018\u20138-113) []. Informed consent was obtained from all respondents before the interviews.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"254"}}